Clik here to view.
Clik here to view.
Prana Receives First Orphan Drug Designation from the FDA for the Treatment...
MELBOURNE, Australia & SAN FRANCISCO Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) (“Prana” or “the Company”) has today announced the US Food and Drug Administration (FDA) has granted Orphan...
View ArticleClik here to view.
武田薬品：2018年度第3四半期（4-12月期）の連結業績について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 (東証:4502)(NYSE:TAK)： 実質的な売上収益は＋4.8％、医療用医薬品の成長が牽引し、すべての地域で増収 実質ベースの売上収益の成長率は、タケダの成長ドライバー（消化器系疾患領域、オンコロジー、ニューロサイエンス、新興国事業）の＋10.5％の継続的な伸長により、対前年同期＋4.8％...
View ArticleClik here to view.
Takeda Reports Third Quarter FY2018 Results
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): Underlying Revenue +4.8% year-to-date with growth of prescription drug portfolio in all regions Solid Underlying Revenue...
View ArticleClik here to view.
武田连续第二年荣膺享有盛誉的全球杰出雇主奖
日本大阪 (美国商业资讯)–武田药品工业株式会社[TOKYO: 4502 / NYSE: TAK]（“武田”）今天宣布其成为2019年荣膺全球杰出雇主(Top Employer®)奖项的十二家公司之一。此奖项认证成立于25年前，每年由杰出雇主调研机构(Top Employers...
View ArticleClik here to view.
Dr. Reddy’s Q3 FY19 Financial Results
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter ended December 31, 2018 under International...
View ArticleClik here to view.
Dr. Reddy’s Announces the Appointment of Marc Kikuchi to Lead Its Generics...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the...
View ArticleClik here to view.
LEO Pharma Scientists Win Innovator of the Year 2019 Award from Innovation...
BALLERUP, Denmark LEO Pharma, a global leader in medical dermatology, today announced that two of the company’s scientists have been awarded Innovation Fund Denmark’s Innovator of the Year Award...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Continues its Voluntary Nationwide Recall of...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that its wholly owned subsidiary, Dr Reddy’s Laboratories, Inc, is continuing...
View ArticleClik here to view.
武田薬品のデング熱ワクチン候補がピボタル第3相有効性試験で主要評価項目を達成
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社[TSE:4502 / NYSE:TAK]（以下、武田薬品）は本日、当社デング熱ワクチン候補がピボタル第3相試験で主要有効性評価項目を達成したと発表しました。Tetravalent Immunization against Dengue Efficacy...
View ArticleClik here to view.
Rockwood Equity Partners and SYNEO Team Partner on Management Buyout
WEST PALM BEACH, Fla. Rockwood Equity Partners, a lower middle market private investment firm, announced today that it has completed a management buyout of SYNEO, a provider of manufacturing...
View ArticleClik here to view.
BioventusがマレーシアでDUROLANE®を発売し、独占販売の提携企業にAthrotechを選定
蘭ホーフトドルプ （ビジネスワイヤ） — オーソバイオロジクス・ソリューションの世界的リーダー企業のBioventusは、変形性関節症治療用の関節内単回注射液DUROLANEをマレーシアで発売し、同市場での独占販売の提携企業にAthrotechを選定しました。 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：...
View ArticleClik here to view.
Takeda Announces Results from First-of-Its-Kind Phase IIIb/IV Trial PROPEL –...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), the global biotechnology leader in rare diseases, has today announced results from its phase...
View ArticleClik here to view.
European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the...
CAMBRIDGE, Mass. and OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) extended the current marketing authorization of ADCETRIS...
View ArticleClik here to view.
Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved...
NEW YORK & TOKYO Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today results from the Phase 3 ARCHES trial in men...
View ArticleClik here to view.
澳美集团与美国 Vitruvias Therapeutics Inc. 签订半固体制剂合作协议
香港 & 阿拉巴馬州奧本 澳美集团与总部设在亚拉巴马州奥本 (Auburn) 的制药公司 Vitruvias Therapeutics Inc. (下称 Vitruvias) 签署了一项共同开发与生产外用半固体制剂的合作协议，产品将会在美国及中国市场上市。Vitruvias 负责美国的分销工作，而澳美则会负责中国以及其他指定的亚洲区域的市场销售。产品将由澳美在香港新设的 PIC/S...
View ArticleClik here to view.
武田公布2018财年第三季度业绩
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO:4502, NYSE:TAK)： 本年至今基础营收增长+4.8%，处方药产品组合在各个地区均有增长 基础营收稳步增长+4.8%，武田的增长引擎（胃肠药、肿瘤药、神经科药物和新兴市场）维持了强劲势头 ，增长+10.5%。 主要增长产品Entyvio...
View ArticleClik here to view.
Dr. Reddy’s Laboratories launches Tadalafil Tablets USP in the U.S. Market
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the...
View ArticleClik here to view.
武田在EAHAD 2019上发布同类首创PK指导下预防性治疗IIIb/IV期PROPEL随机试验结果，该试验评估血友病A的较高第VIII因子水平
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 罕见病领域的全球性生物技术领先者武田药品工业株式会社(TSE:4502/NYSE:TAK)（“武田”）今天在欧洲血友病及相关疾病学会(EAHAD)第12届年会上发布了ADYNOVATE...
View ArticleClik here to view.
H.I.G.Capital完成对Taconic Biosciences的收购
波士顿 –(美国商业资讯)–旗下管理着300亿美元股权资本的领先全球私募股权投资公司H.I.G.Capital (“H.I.G.”)欣然宣布，其附属公司之一已与Taconic Biosciences, Inc.（“Taconic”或“该公司”）管理团队合作支持该公司成长为制药、生物科技、合同研究组织(CRO)和学术研究行业领先的全球研究模型和服务提供商。...
View Article